These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

635 related articles for article (PubMed ID: 27137897)

  • 21. Gut dysbiosis and age-related neurological diseases; an innovative approach for therapeutic interventions.
    Holmes A; Finger C; Morales-Scheihing D; Lee J; McCullough LD
    Transl Res; 2020 Dec; 226():39-56. PubMed ID: 32755639
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Effects and Mechanisms of Probiotics, Prebiotics, Synbiotics, and Postbiotics on Metabolic Diseases Targeting Gut Microbiota: A Narrative Review.
    Li HY; Zhou DD; Gan RY; Huang SY; Zhao CN; Shang A; Xu XY; Li HB
    Nutrients; 2021 Sep; 13(9):. PubMed ID: 34579087
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Gut Microbiota, in the Halfway between Nutrition and Lung Function.
    Espírito Santo C; Caseiro C; Martins MJ; Monteiro R; Brandão I
    Nutrients; 2021 May; 13(5):. PubMed ID: 34069415
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The Roles of Inflammation, Nutrient Availability and the Commensal Microbiota in Enteric Pathogen Infection.
    Stecher B
    Microbiol Spectr; 2015 Jun; 3(3):. PubMed ID: 26185088
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Effect of a Nutritional Intervention on the Intestinal Microbiota of Vertically HIV-Infected Children: The Pediabiota Study.
    Sainz T; Gosalbes MJ; Talavera-Rodríguez A; Jimenez-Hernandez N; Prieto L; Escosa L; Guillén S; Ramos JT; Muñoz-Fernández MÁ; Moya A; Navarro ML; Mellado MJ; Serrano-Villar S
    Nutrients; 2020 Jul; 12(7):. PubMed ID: 32708743
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Microbiota medicine: towards clinical revolution.
    Gebrayel P; Nicco C; Al Khodor S; Bilinski J; Caselli E; Comelli EM; Egert M; Giaroni C; Karpinski TM; Loniewski I; Mulak A; Reygner J; Samczuk P; Serino M; Sikora M; Terranegra A; Ufnal M; Villeger R; Pichon C; Konturek P; Edeas M
    J Transl Med; 2022 Mar; 20(1):111. PubMed ID: 35255932
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Microbial contributions to chronic inflammation and metabolic disease.
    Shanahan F; Sheehan D
    Curr Opin Clin Nutr Metab Care; 2016 Jul; 19(4):257-62. PubMed ID: 27097361
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Implications of Gut Microbiota in Complex Human Diseases.
    Yu D; Meng X; de Vos WM; Wu H; Fang X; Maiti AK
    Int J Mol Sci; 2021 Nov; 22(23):. PubMed ID: 34884466
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Intestinal Microbiota as a Contributor to Chronic Inflammation and Its Potential Modifications.
    Potrykus M; Czaja-Stolc S; Stankiewicz M; Kaska Ł; Małgorzewicz S
    Nutrients; 2021 Oct; 13(11):. PubMed ID: 34836095
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Human gut microbiota/microbiome in health and diseases: a review.
    Gomaa EZ
    Antonie Van Leeuwenhoek; 2020 Dec; 113(12):2019-2040. PubMed ID: 33136284
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Therapeutic interventions for gut dysbiosis and related disorders in the elderly: antibiotics, probiotics or faecal microbiota transplantation?
    Vemuri RC; Gundamaraju R; Shinde T; Eri R
    Benef Microbes; 2017 Apr; 8(2):179-192. PubMed ID: 28008784
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Human gut microbiome: Therapeutic opportunities for metabolic syndrome-Hype or hope?
    Horvath A; Zukauskaite K; Hazia O; Balazs I; Stadlbauer V
    Endocrinol Diabetes Metab; 2024 Jan; 7(1):e436. PubMed ID: 37771199
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Current understanding of microbiota- and dietary-therapies for treating inflammatory bowel disease.
    Eom T; Kim YS; Choi CH; Sadowsky MJ; Unno T
    J Microbiol; 2018 Mar; 56(3):189-198. PubMed ID: 29492876
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Understanding the Role of the Gut Microbiome and Microbial Metabolites in Obesity and Obesity-Associated Metabolic Disorders: Current Evidence and Perspectives.
    Vallianou N; Stratigou T; Christodoulatos GS; Dalamaga M
    Curr Obes Rep; 2019 Sep; 8(3):317-332. PubMed ID: 31175629
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Gut microbiota and obesity: An opportunity to alter obesity through faecal microbiota transplant (FMT).
    Lee P; Yacyshyn BR; Yacyshyn MB
    Diabetes Obes Metab; 2019 Mar; 21(3):479-490. PubMed ID: 30328245
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Microbial dysbiosis-induced obesity: role of gut microbiota in homoeostasis of energy metabolism.
    Amabebe E; Robert FO; Agbalalah T; Orubu ESF
    Br J Nutr; 2020 May; 123(10):1127-1137. PubMed ID: 32008579
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Prebiotic and Probiotic Modulation of the Microbiota-Gut-Brain Axis in Depression.
    Radford-Smith DE; Anthony DC
    Nutrients; 2023 Apr; 15(8):. PubMed ID: 37111100
    [TBL] [Abstract][Full Text] [Related]  

  • 38. N-3 polyunsaturated fatty acids: An innovative strategy against obesity and related metabolic disorders, intestinal alteration and gut microbiota dysbiosis.
    Bellenger J; Bellenger S; Escoula Q; Bidu C; Narce M
    Biochimie; 2019 Apr; 159():66-71. PubMed ID: 30690133
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Possibilities of therapeutic manipulation of the gut microbiota].
    Drastich P; Bajer L; Kverka M
    Vnitr Lek; 2018; 64(6):665-671. PubMed ID: 30223665
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Cardiovascular Diseases of Developmental Origins: Preventive Aspects of Gut Microbiota-Targeted Therapy.
    Hsu CN; Hou CY; Hsu WH; Tain YL
    Nutrients; 2021 Jul; 13(7):. PubMed ID: 34371800
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 32.